跳至主要内容
临床试验/NCT02335294
NCT02335294已完成2 期

A Phase 2, Randomized, Double-Blind, Placebo- and Active-controlled Study of TRV130 for the Treatment of Acute Postoperative Pain Following Abdominoplasty

Trevena Inc.0 个研究点目标入组 200 人开始时间: 2014年12月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
Trevena Inc.
入组人数
200
主要终点
Time Weighted Average (TWA) Change From Baseline in Pain Score Over 24 Hours Between TRV130 and Placebo

研究概览

简要总结

The primary objective is to evaluate the analgesic efficacy of IV TRV130 compared with placebo in patients with acute postoperative pain following abdominoplasty.

详细描述

The primary objective is to evaluate the analgesic efficacy of intravenous (IV) TRV130 administered via patient controlled analgesia device (PCA) compared with placebo administered via PCA in patients with moderate to severe, acute postoperative pain following abdominoplasty.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • >=18 and <=65 years of age.
  • Plans to undergo an abdominoplasty procedure with no additional collateral procedures.
  • Is able to understand and comply with the procedures and study requirements, and to provide written informed consent before any study procedure.

排除标准

  • ASA Physical Status Classification System classification of P3 or worse.
  • Has surgical or post-surgical complications.
  • Has clinically significant medical conditions or history of such conditions that may interfere with the interpretation of efficacy, safety, or tolerability data obtained in the trial, or may interfere with the absorption, distribution, metabolism, or excretion of drugs.
  • Has previously participated in another TRV130 clinical study.

研究组 & 干预措施

Morphine

Active Comparator

干预措施: Morphine (Drug)

Placebo

Placebo Comparator

干预措施: Placebo (Drug)

TRV130

Experimental

干预措施: TRV130 (Drug)

结局指标

主要结局

Time Weighted Average (TWA) Change From Baseline in Pain Score Over 24 Hours Between TRV130 and Placebo

时间窗: 24-hours

Pain intensity will be evaluated using an 11-point (0-10) Numeric Pain Rating Scale (NPRS), with higher numbers indicating a higher pain intensity, administered over 24 hours. Time weighted average change from baseline is calculated using the following: time weighted sum of pain intensity differences (SPID) divided by a constant (24 hours) to yield values on the 0-10 NPRS.

次要结局

  • Time Weighted Average (TWA) Change From Baseline in Pain Score Over 24 Hours Between TRV130 and Morphine(24-hours)

研究者

发起方
Trevena Inc.
申办方类型
Industry
责任方
Sponsor

相似试验